logo
Researchers make concerning discovery about health risk during pregnancy: 'Further research is needed'

Researchers make concerning discovery about health risk during pregnancy: 'Further research is needed'

Yahoo12-03-2025

A new study suggests that exposure to per- and polyfluoroalkyl substances — also known as PFAS or "forever chemicals" — could lead to lower placental weights, potentially posing health concerns for maternal and newborn health.
Researchers set out to investigate the potential of "impaired placental structure and function" in humans due to PFAS exposure because it had previously been observed in animals like mice and rabbits.
The authors noted that previous studies have produced mixed results regarding the link between PFAS exposure and placental weight. For instance, one previous study found no correlation. However, they added that few human-based studies exist.
The France-based research team measured PFAS concentrations in the blood of 484 pregnant women. At birth, their placentas were weighed and tissues analyzed. They found that women in the moderate-to-higher PFAS exposure group had, on average, lower placental weights compared to those with lower levels in their systems.
"Further research is needed to confirm these findings and elucidate placental mechanisms influenced by PFAS, alone or in combination with other environmental chemicals," the authors wrote.
According to Oregon Health & Science University, small placentas may be indicative of malnourishment and a lack of oxygen supply in the womb. Per OHSU, they "are also associated with increased risk of chronic disease later in life."
The new research regarding lower placental weights adds to a growing body of evidence linking PFAS with negative health outcomes. One study revealed that exposure to PFAS can alter the expressions of certain genes within the brain. Another paper linked these chemicals to an increased risk of cardiovascular diseases in postmenopausal women.
These "forever chemicals" have also been associated with an increased risk of some cancers, low birth weight, decreased fertility, interference with the body's natural hormones, reduced ability of the immune system to fight infections, and other health concerns, according to the U.S. Environmental Protection Agency.
Though PFAS compounds are known for being persistent in the environment, scientists are identifying new ways to help break them down. For example, researchers at the University of Illinois found a way to remove the full spectrum of PFAS from water in a single process. Scientists at the University of Rochester are doing similar work.
Do you worry about having toxic forever chemicals in your home?
Majorly
Sometimes
Not really
I don't know enough about them
Click your choice to see results and speak your mind.
You can limit your exposure by purchasing from PFAS-free brands (identified here by PFAS Central), skipping on nonstick cookware, and limiting your purchases of stain- or water-resistant clothing.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sanofi buys US biopharma group Blueprint in $9.1 billion deal
Sanofi buys US biopharma group Blueprint in $9.1 billion deal

Yahoo

time2 hours ago

  • Yahoo

Sanofi buys US biopharma group Blueprint in $9.1 billion deal

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.

Bat-eared foxes return to zoo after 30 year wait
Bat-eared foxes return to zoo after 30 year wait

Yahoo

time3 hours ago

  • Yahoo

Bat-eared foxes return to zoo after 30 year wait

A zoo has welcomed two rare bat-eared foxes, 30 years on from when the animal was last there. The two African foxes, which are known for their 13cm (five inches) tall ears, are said to be settling in well at Chester Zoo. Sisters Maasai and Malindi will live alongside 12 porcupines in the zoo's new Heart of Africa habitat and will play a part in the zoo's conservation work. David White, Chester Zoo's team manager, said: "It's incredibly exciting to welcome bat-eared foxes back to Chester Zoo after a 30-year hiatus and they're a wonderful addition to our new Heart of Africa habitat." "They're a truly unique and fascinating species with some amazing adaptations," he added. He said their "enormous ears aren't just for show – they act like satellite dishes and help the foxes detect the tiniest of movements coming from insects beneath the ground, allowing them to detect prey with pinpoint accuracy". Zoo conservationists brought the sisters over to Chester from a zoo in Paris, France, with one of the sisters set to be introduced to a male fox as part of efforts to safeguard the little-known species. Bat-eared foxes were given their name due to their distinctive oversized ears and they are found in the open savannahs and arid grasslands of eastern and southern Africa. In the wild, bat-eared foxes face increasing threats, largely due to habitat loss caused by agriculture, human encroachment and hunting, a zoo spokesperson said. David White said that like many species found in the African savannah, bat-eared foxes were under threat as their habitat became more fragmented as a result of human activity. "That's why our teams are on the ground in several national parks across Kenya and Uganda safeguarding some of the continent's rarest species like northern giraffe, giant pangolins, mountain bongo and Eastern black rhino," he said. "By protecting these species and their habitats we're also helping many of Africa's little known species like bat-eared foxes, that share the same habitats, to go on to thrive once again." Read more stories from Cheshire on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC North West on X. You can also send story ideas via Whatsapp to 0808 100 2230. 'Giraffes, zebras, antelopes and ostriches have become housemates' Breeding hope as rare fossa arrives at zoo from US Sloth has pioneering surgery to cure toothache Chester Zoo

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store